Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus.

AIM This study aimed to develop a novel influenza A vaccine by conjugating the highly conserved extracellular region of the matrix 2 protein (M2e) of influenza A virus to gold nanoparticles (AuNPs) and to test the vaccine in a mouse influenza challenge model. MATERIALS & METHODS Citrate-reduced AuNPs (diameter: 12 nm) were synthesized, and characterized by transmission electron microscopy and dynamic light scattering. M2e was conjugated to AuNPs through thiol-gold interactions to form M2e-AuNP conjugates. Particle stability was confirmed by UV-visible spectra, and M2e conjugation was further characterized by x-ray photoelectron spectroscopy. Mice were immunized with M2e-AuNPs with or without CpG (cytosine-guanine rich oligonucleotide) as an adjuvant with appropriate control groups. Sera was collected and M2e-specific immunoglobulin (IgG) was measured, and immunized mice were challenged with PR8-H1N1 influenza virus. RESULTS M2e-capped AuNPs could be lyophilized and stably resuspended in water. Intranasal vaccination of mice with M2e-AuNP conjugates induced M2e-specific IgG serum antibodies, which significantly increased upon addition of soluble CpG as adjuvant. Upon challenge with lethal PR8, mice vaccinated with M2e-AuNP conjugates were only partially protected, while mice that received soluble CpG as adjuvant in addition to M2e-AuNP were fully protected. CONCLUSION Overall, this study demonstrates the potential of using the M2e-AuNP conjugates with CpG as an adjuvant as a platform for developing an influenza A vaccine.

[1]  C. Siegrist,et al.  CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Weipeng Cao,et al.  Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. , 2012, Biomaterials.

[3]  C. Bode,et al.  CpG DNA as a vaccine adjuvant , 2003, Expert review of vaccines.

[4]  Alaaldin M. Alkilany,et al.  Gold nanoparticles in biology: beyond toxicity to cellular imaging. , 2008, Accounts of chemical research.

[5]  Neus G Bastús,et al.  Peptides conjugated to gold nanoparticles induce macrophage activation. , 2009, Molecular immunology.

[6]  M. Tebianian,et al.  Influenza A viruses: why focusing on M2e-based universal vaccines , 2011, Virus Genes.

[7]  F. Albericio,et al.  Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. , 2011, Molecular pharmaceutics.

[8]  K. Mozdzanowska,et al.  Prospects for Universal Influenza Virus Vaccine , 2006, Emerging infectious diseases.

[9]  G. Danscher,et al.  Ultrastructural autometallography: a method for silver amplification of catalytic metals. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  R. Lamb,et al.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface , 1985, Cell.

[11]  Yanli Liu,et al.  Synthesis, stability, and cellular internalization of gold nanoparticles containing mixed peptide-poly(ethylene glycol) monolayers. , 2007, Analytical chemistry.

[12]  F. Albericio,et al.  Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide receptor of a tumor cell line. , 2010, Bioconjugate chemistry.

[13]  D. Astruc,et al.  Gold Nanoparticles: Assembly, Supramolecular Chemistry, Quantum‐Size‐Related Properties, and Applications Toward Biology, Catalysis, and Nanotechnology. , 2004 .

[14]  Shibo Jiang,et al.  An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses , 2010, Virology Journal.

[15]  Yao-Ching Hung,et al.  Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide , 2010, Nanotechnology.

[16]  Bradley Duncan,et al.  Gold nanoparticle platforms as drug and biomacromolecule delivery systems. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Irshad Hussain,et al.  Rational and combinatorial design of peptide capping ligands for gold nanoparticles. , 2004, Journal of the American Chemical Society.

[18]  Rosemary L. Smith,et al.  Preparation of surfactant-stabilized gold nanoparticle–peptide nucleic acid conjugates , 2010 .

[19]  Arezou A Ghazani,et al.  Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.

[20]  Aiguo Wu,et al.  A gold nanoparticle-based immunochromatographic assay: the influence of nanoparticulate size. , 2012, The Analyst.

[21]  M. Bandehpour,et al.  Immunization with M2e-Displaying T7 Bacteriophage Nanoparticles Protects against Influenza A Virus Challenge , 2012, PloS one.

[22]  Lev Dykman,et al.  Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. , 2011, Chemical Society reviews.

[23]  Scott A. Brown,et al.  Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza , 2006, Clinical and Vaccine Immunology.

[24]  J. Taubenberger,et al.  Characterization of the 1918 “Spanish” Influenza Virus Matrix Gene Segment , 2002, Journal of Virology.

[25]  Jing Luo,et al.  α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice. , 2011, Vaccine.

[26]  S. A. Staroverov,et al.  Obtainment of Polyclonal Antibodies to Clenbuterol with the Use of Colloidal Gold , 2007, Immunopharmacology and immunotoxicology.

[27]  Keishiro Tomoda,et al.  Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. , 2008, Colloids and surfaces. B, Biointerfaces.

[28]  Stephan Link,et al.  Size and temperature dependence of the plasmon absorption of colloidal gold nanoparticles , 1999 .

[29]  R. Lamb,et al.  Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. , 1991, Virology.

[30]  T. Tumpey,et al.  Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. , 2006, Vaccine.

[31]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[32]  S. Franzen,et al.  Assembly and characterization of biomolecule-gold nanoparticle conjugates and their use in intracellular imaging. , 2005, Methods in molecular biology.

[33]  P. Jain,et al.  Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine. , 2006, The journal of physical chemistry. B.

[34]  Lev A. Dykman,et al.  Adjuvant properties of gold nanoparticles , 2010 .

[35]  W. Fiers,et al.  Improved design and intranasal delivery of an M2e-based human influenza A vaccine. , 2006, Vaccine.

[36]  W. Fiers,et al.  Universal influenza A vaccine: optimization of M2-based constructs. , 2005, Virology.

[37]  W. Fiers,et al.  The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. , 2006, Vaccine.

[38]  Ying-hua Chen,et al.  The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. , 2009, Vaccine.

[39]  J. Shiver,et al.  Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. , 2006, Journal of pharmaceutical sciences.

[40]  Y. Hung,et al.  Assessment of the In Vivo Toxicity of Gold Nanoparticles , 2009, Nanoscale research letters.

[41]  Bong Hyun Chung,et al.  Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. , 2009, Toxicology and applied pharmacology.

[42]  J. Snick,et al.  IgG2a restriction of murine antibodies elicited by viral infections , 1987, The Journal of experimental medicine.

[43]  W. Stach,et al.  ICP-MS: a powerful technique for quantitative determination of gold nanoparticles without previous dissolving , 2009 .

[44]  Sabine Neuss,et al.  Size-dependent cytotoxicity of gold nanoparticles. , 2007, Small.

[45]  R. Lamb,et al.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. , 1985, Cell.

[46]  J. Shiver,et al.  Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. , 2009, Vaccine.

[47]  W. Fiers,et al.  Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. , 2008, Vaccine.

[48]  C. Soto,et al.  Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. , 2010, Biochemical and biophysical research communications.

[49]  Lawrence Tamarkin,et al.  Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery , 2004, Drug delivery.

[50]  M. Fujii,et al.  Resistance to influenza A virus infection by antigen-conjugated CpG oligonucleotides, a novel antigen-specific immunomodulator. , 2005, Biochemical and biophysical research communications.

[51]  Min-Chul Kim,et al.  Influenza Virus-Like Particles Containing M2 Induce Broadly Cross Protective Immunity , 2011, PloS one.

[52]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[53]  Nikolai G. Khlebtsov,et al.  Gold Nanoparticles in Biomedical Applications: Recent Advances and Perspectives , 2012 .

[54]  R. K. Evans,et al.  Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. , 2008, Vaccine.

[55]  W. Kowalczyk,et al.  Strategies and limitations in dendrimeric immunogen synthesis. The influenza virus M2e epitope as a case study. , 2010, Bioconjugate chemistry.

[56]  T. Tumpey,et al.  Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1 , 2007, Emerging infectious diseases.

[57]  J. Kimling,et al.  Turkevich method for gold nanoparticle synthesis revisited. , 2006, The journal of physical chemistry. B.